Biomarker ID | 103 |
PMID | 16322291 |
Year | 2005 |
Biomarker | Methylation status of GSTP1 |
Biomarker Basis | Methylation Based |
Biomolecule | mRNA |
Source | Tissue |
Subjects | Humans |
Regulation | Hypermethylated in Patients who relapsed |
Odds Ratio/Hazard Ratio/Relative Risk | HR: 0.23 (95% CI: 0.09-0.64) |
Effect on Pathways | Pathways include: Arachidonate epoxygenase/epoxide hydrolase pathway, Multi-drug resistance factors,Glutathione conjugation,Glutathione metabolism,Prostate cancer |
Experiment | Time to Progression |
Type of Biomarker | Prognostic |
Cohort | 74 patients who underwent radical prostatectomy for localised Prostate Cancer were chosen for the study. Over a period of 9 years 37 patients relapsed or died from recurrance. All the patients had a Gleason score of 7. |
Senstivity | NA |
Specificity | NA |
AUC | NA |
Accuracy | NA |
Level Of Significance | P = 0.004 |
Method Used | quantitative methylation specific PCR (QMSP) |
Clinical | No |
Remarks | HR for Multivariate Analysis (Considering Age, GSTP1, and APC). The major statistical end point of this study was time to progression (TTP). Progression included PSA elevations of >0.2 ng/mL, metastasis, and or death |
Clinical Trial Number | NA |
Degree Of Validity | Not validated on independent patient dataset |
Technical Name | GSTP1 |